{
    "clinical_study": {
        "@rank": "9862", 
        "arm_group": [
            {
                "arm_group_label": "Group A (Normal renal function): Daclatasvir", 
                "arm_group_type": "Experimental", 
                "description": "Daclatasvir 60 mg tablet by mouth single dose on Day 1"
            }, 
            {
                "arm_group_label": "Group B (End Stage Renal Disease): Daclatasvir", 
                "arm_group_type": "Experimental", 
                "description": "Daclatasvir 60 mg tablet by mouth single dose on Day 1"
            }, 
            {
                "arm_group_label": "Group C (Moderate renal impairment): Daclatasvir", 
                "arm_group_type": "Experimental", 
                "description": "Daclatasvir 60 mg tablet by mouth single dose on Day 1"
            }, 
            {
                "arm_group_label": "Group D (Severe renal impairment): Daclatasvir", 
                "arm_group_type": "Experimental", 
                "description": "Daclatasvir 60 mg tablet by mouth single dose on Day 1"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of renal function impairment on the single\n      dose pharmacokinetics of Daclatasvir."
        }, 
        "brief_title": "Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Meet renal function criteria in one of four categories\n\n        Exclusion Criteria:\n\n        - Unstable or uncontrolled medical conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830205", 
            "org_study_id": "AI444-063"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A (Normal renal function): Daclatasvir", 
                "Group B (End Stage Renal Disease): Daclatasvir", 
                "Group C (Moderate renal impairment): Daclatasvir", 
                "Group D (Severe renal impairment): Daclatasvir"
            ], 
            "intervention_name": "Daclatasvir", 
            "intervention_type": "Drug", 
            "other_name": "BMS-790052"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 13, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Davita Clinical Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Single Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Primary endpoint is the single dose area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Daclatasvir", 
            "safety_issue": "No", 
            "time_frame": "15 time points up to Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830205"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Unbound maximum observed plasma concentrations (Cmax\u03bc) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "AUC(INF) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Unbound area under the plasma concentration-time curve from time zero extrapolated to infinity time [AUC(INF)u] of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Plasma half-life (T-HALF) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Apparent total body clearance (CLT/F) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Unbound apparent clearance (CLU/F) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Percent urinary recovery (%UR) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Renal clearance (CLR) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "measure": "Apparent volume of distribution (Vd/F) of Daclatasvir", 
                "safety_issue": "No", 
                "time_frame": "15 time points up to Day 5"
            }, 
            {
                "description": "Safety assessments will be based on medical review of adverse event (AE) reports and the results of vital sign measurements, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests. The incidence of observed adverse events will be tabulated and reviewed for potential significance and clinical importance", 
                "measure": "Safety and tolerability endpoints include AEs, serious AEs, AEs leading to discontinuation, deaths, and marked laboratory abnormalities, vital signs and ECG measurements", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 5"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}